ReviewJournal of menopausal medicine2022
Hormone Therapy and Risk of Breast Cancer: Where Are We Now?
Review in Journal of menopausal medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A network meta-analysis of acupuncture therapy for female insomnia and negative emotions from the perspective of the perimenopausal window.Frontiers in neurology · 2025Pooled it
- Optogenetic manipulation of estrogen receptor signaling to improve estrogen deficiency.iScience · 2026Article
- LGBTQ+ persons, queer bioethics, and inclusivity in stem cell research and regenerative medicine.Regenerative medicine · 2025Review
- Changes in female cancer diagnostic billing rates over the COVID-19 period in the Ontario Health Insurance Plan.Therapeutic advances in medical oncology · 2025Article
- Article
- A Recent Review of the Management of Postmenopausal Symptoms in Breast Cancer Survivors.Journal of menopausal medicine · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Several studies have examined the clinical benefits of hormone replacement therapy (HRT). However, because long-term use of HRT has been implicated as a risk factor for the development of breast cancer, some women remain skeptical when considering this therapy to address their vasomotor symptoms. Hence, physicians and nurses should actively engage in constructive discourse with their patients regarding HRT while specifically reviewing the potential risks of its extended use as well as provide the available medical alternatives the patients could potentially use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.